Arena's Belviq scripts spike on DTC, stepped-up field force; Sanofi inks cancer marketing pact with India's Emcure;

> Arena Pharmaceuticals ($ARNA) reported a 43% rise in second-quarter sales of its obesity drug Belviq as DTC ads and a beefed-up sales force gained momentum. Report

> Sanofi ($SNY) tapped India's Emcure Pharmaceuticals to market its oncology drugs Taxotere, Jevtana, Fludara and Fasturtec in that country. Report

> It's official: Roche ($RHHBY) has won approval to market Avastin in Europe as a treatment for recurrent ovarian cancer resistant to platinum-based chemo. Release | Report

> Pfizer's ($PFE) Enbrel scored a European nod to treat a rare inflammatory joint disorder at early stages of the disease. Report

> Ashfield Healthcare recruited Wendy Wolf away from Publicis Touchpoint Solutions to be its SVP of commercial and clinical operations. Report

And Finally... A new scientific review found that aspirin could stave off bowel and stomach cancers. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.